Synthetic ovine corticotropin releasing factor (oCRF) and human CRF were given as an intravenous bolus to 6 healthy volunteers in 4 different dosages (oCRF: 25, 50, 100 and 200 µg) respectively, 2 different dosages (hCRF: 50 and 100 µg). ACTH and cortisol were measured over a 2-hour period after CRF injection. CRF immunoreactivity was measured with a newly developed homologous radioimmunoassay for both oCRF and hCRF. All CRF dosages tested led to a definite ACTH response compared to placebo control. No dose dependency of side effects was observed. Furthermore, there was no clear-cut dose response relationship between the injected CRF dosages and the maximal ACTH- and cortisol levels. However, when the area under the ACTH and cortisol-response curves after oCRF were compared a dose-response relationship emerged, which could not be demonstrated in the same way for the two hCRF dosages. Serum CRF immunoreactivity correlated to the injected dosage. The halftime of serum disappearance for oCRF was 18 min, and hCRF, 9 min. The maximal ACTH responses after injection of oCRF and hCRF were not significantly different.

Keywords:
Corticotropin releasing factor, ovine (oCRF), dose response in humans, Corticotropin releasing factor, human (hCRF), dose response in humans, Radioimmunoassay for oCRF, hCRF, ACTH and cortisol
This content is only available via PDF.
© 1986 S. Karger AG, Basel
1986
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.